France Expands BOT–BAL Immunotherapy Access for Ovarian Cancer and Soft Tissue Sarcoma

here are the citations, formatted for clarity:

1. France Expands National AAC Access for Agenus’ botensilimab, Balstilimab for Ovarian Cancer and Soft Tissue Sarcomas. BioSpace.January 15,2026. Accessed January 15, 2026. https://www.biospace.com/press-releases/france-expands-national-aac-access-for-agenus-botensilimab-balstilimab-for-ovarian-cancer-and-soft-tissue-sarcomas

2. Expanded Access. U.S. Food and Drug Management. August 9, 2025. Accessed January 15, 2026. https://www.fda.gov/news-events/public-health-focus/expanded-access

3. Agenus Announces Closing of $141M Strategic Collaboration with Zydus Lifesciences to Advance BOT+BAL and Strengthen U.S. Manufacturing Readiness.Agenus. News release.January 15, 2026.accessed January 15, 2026. https://investor.agenusbio.com/news/news-details/2026/Agenus-Announces-Closing-of-141M-Strategic-Collaboration-with-Zydus-Lifesciences-to-Advance-BOTBAL-and-Strengthen-U-S–Manufacturing-Readiness/default.aspx